Emmessar Biotech & Nutrition Ltd

EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373 / 35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

Date: August 07, 2026

To,
The Manager
Listing Department,
Bombay Stock Exchange Limited,
P. J. Tower, Dalal Street,
Mumbai – 400 001

Ref: -Security Code No.524768
Sub: Outcome of Board Meeting

The Board of Directors at their meeting held today i.e. August 07, 2026 has transacted the following items of business:

1. **Unaudited Financial Results for the Quarter ended June 30, 2026:**
Pursuant to Regulation 33(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are forwarding herewith a copy of Unaudited Financial Results for the Quarter ended 30.06.2026.

   The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 07.08.2026 (i.e today).

   We also enclose "Limited Review Report" dated 07.08.2026, issued by Statutory Auditors, M/s. V. Nagarajan & Co., Chartered Accountant(s), FRN No.: 004879N, in respect of Unaudited Financial Results for the Quarter ended 30.06.2026. The results are attached at "Annexure A".

2. **Annual General Meeting:**
The 34th Annual General Meeting of the Company is scheduled to be held on Tuesday September 29, 2025 at 10:30 a.m. through video conferencing pursuant to MCA General Circular Nos. 14/2020, 17/2020, 20/2020, 02/2021, 21/2021, 02/2022, 10/2022, 09/2023, 09/2024 and 03/2025; dated April 8, 2020, April 13, 2020, May 5, 2020, January 13, 2021, December 14, 2021, May 5, 2022, December 28, 2022, September 25, 2023, September 19, 2024 and September 22, 2025 respectively ("MCA Circulars") (hereinafter collectively referred to as "MCA Circulars") and Circular No. SEBI/HO/ CFD/CMD1/CIR/P/2020/79 dated May 12, 2020, Circular No. SEBI/HO/CFD/ CMD2/CIR/P/2022/62 dated May 13, 2022, Circular No. SEBI/HO/ CFD/PoD-2/P/CIR/2023/4 dated January 5, 2023, Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 7, 2023 and Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024 ("SEBI circulars"). In compliance with these MCA and SEBI Circulars, there has been certain relaxations from compliance with certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), issued in this behalf.

   In compliance with these MCA and SEBI Circulars, provisions of the Companies Act, 2013 (the "Act") and the Listing Regulations, the ensuing 34th AGM of the Company

EMMESSAR BIOTECH & NUTRITION LTD. MUMBAI

EMMESSAR BIOTECH & NUTRITION LIMITED
29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373 / 35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

will be conducted through VC/ OAVM facility, which does not require physical presence of members at a common venue. The deemed venue for the 34th AGM shall be the Registered Office of the Company.

3. **E voting and Cut-off date:**
   In compliance with the provisions of Section 108 of the Companies Act, 2013, read with Rule 20 Companies (Management and Administration) Rules as amended up to date and Regulation 44 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Company has decided to provide the facility to members to exercise their right to vote at the Annual General Meeting (AGM) by electronic means and the business may be transacted through e-Voting services provided by MUFG Intime India Private Limited formerly known as Link Intime India Pvt. Ltd (MUFG).

   The cutoff date for the limited purpose of remote e-voting is September 22, 2026.

   The remote e-voting period will commence on Saturday, September 26, 2026 at 09:00 A.M. IST and end on Monday, September 28, 2026 at 5:00 P.M IST. During this period shareholders of the Company, holding shares either in physical form or in dematerialised form, as on cut-off date i.e. Tuesday, September 22, 2026, may cast their vote electronically.

The Meeting commenced at 12:15 pm and concluded at 13:40 p.m.

Kindly take the above on record.

For **EMMESSAR BIOTECH & NUTRITION LIMITED**

EMMESSAR BIOTECH & NUTRITION LTD. MUMBAI

M S Raghavan Ayyangar
(Managing Director)

Encl: As above

V NAGARAJAN & CO.

Chartered Accountants

Limited Review Report on Unaudited Financial Results of Emmessar Biotech & Nutrition Limited for the Quarter ended 30th June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Emmessar Biotech & Nutrition Limited** ("the Company") for the quarter ended 30th June 2026. ("The Statement").

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the statement based on our review.

3. We conducted our review in accordance with the Standards on Review Engagements (SRE) 2410, '*Review on Interim Financial Information Performed by the Independent auditor of the Entity*' issued by the Institute of Chartered Accountants of India. These standards require that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to enquiries of the Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For V Nagarajan & Co.
Chartered Accountants
ICAI Firm Regn. No. 004879N

V. NAGARAJAN & CO. ★ CHARTERED ACCOUNTANTS ★ FRN 004879N

Shankar Cherekupally
Partner
Membership No. 252304
UDIN: 26252304YBATDC7429

Place: Hyderabad
Date: 07th August, 2026

C-1120-1121, 11th Floor, Tower C KLJ Noida One Block-B, Sector-62, Noida-201 309, Uttar Pradesh, India. Ph: 91-124-407 8742--44|
6-3-1191-1196 , 2nd Floor, Brij Tarang Towers, Kundanbagh Colony, Begumpet, Hyderabad, Telangana, 500016, India Ph:- 9395328742

E-mail: contact@vnc.co.in| website:- www.vnc.co.in

EMMESSAR BIOTECH & NUTRITION LIMITED
Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State
CIN: L24110MH1992PLC065942
UNAUDITED FINANCIAL RESULTS (STANDLONE) FOR THE QUARTER ENDED 30TH JUNE 2026

(Rupees in Lakhs)

Sr. No	Particulars	Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	(Refer note 4)	Unaudited	Audited
	PART A				
1	Revenue from Operations	5.93	9.28	9.28	37.08
2	Other Income	53.92	47.34	53.42	203.59
	Total Income (1 + 2)	**59.85**	**56.62**	**62.70**	**240.66**
	PART B				
3	**Expenses**				
	(a) Cost of material consumed	2.36	2.76	1.16	6.23
	(b) Purchase of Stock-trade	0.00	0.00	0.00	0.00
	(c) Change in Inventories of Finished goods	-0.53	0.45	1.94	2.54
	(d) Employee Benefit Expenses	30.32	26.31	24.50	107.91
	(e) Depreciation & Amortisation of Assets	2.27	2.51	2.49	10.01
	(f) Finance cost	0.07	0.06	0.06	0.25
	(g) Other Expenditure	9.06	16.58	9.42	55.75
	Total Expenses (a to g)	**43.55**	**48.67**	**39.57**	**182.70**
4	Profit / (loss) from Operations before exceptional items & Tax (A-B)	16.30	7.96	23.13	57.96
5	Exceptional items	0.00	0.00	0.00	0.00
6	Profit / (loss) before tax (4 - 5)	**16.30**	**7.96**	**23.13**	**57.96**
7	Tax Expenses				
	1. Current Tax	(4.07)	(4.85)	-6.00	(17.65)
	2. Deferred Tax	0.92	0.76	-0.01	3.74
	3. Excess/short provision of earlier years	0.00	(0.45)	0.00	(0.45)
	Total Tax Expense (1+2+3)	(3.15)	(4.54)	(6.01)	(14.37)
8	Net Profit / (loss) after tax (6 - 7)	13.15	3.42	17.12	43.59
9	Less: Other Comprehensive Income	0.00	2.92	0.00	2.92
10	Total comprehensive income for the period and Other Comprehensive Income	**13.15**	**0.50**	**17.12**	**40.67**
11	Paid-up Equity Share Capital	499.61	499.61	499.61	499.61
	(Face Value of the share)	10.00	10.00	10.00	10.00
	Other Equity	-	-	-	311.87
12	Earning per Shares				
	a) Basic	0.26	0.01	0.34	0.81
	b) Diluted	0.26	0.01	0.34	0.81

Notes:

1. The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 7th August 2026 and have been subjected to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS-34) as prescribed under Section 133 of Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rule 2015 and the Companies (Indian Accounting Standards) Amendments Rule 2016 as amended thereafter.
3. The Company operates two segments ie. Healthcare and rent on leasehold land during this quarter.
4. The figures for the quarter ended March 31, 2026, are the balancing figures between audited figures in respect of the full financial year and published year to date reviewed figures for the nine-month period ended December 31, 2025.
5. No Investor Compliant was received for the quarter ended 30th June 2026.
6. Previous years' figures have been regrouped wherever considered necessary.

Mumbai
07-Aug-26

Srinivasa Raghavan Mathurakavi Ayyangar
Chairman & Managing Director
DIN: 00090266

EMMESSAR BIOTECH & NUTRITION LIMITED
Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State
CIN: L24110MH1992PLC065942
Segmentwise Revenue, Results and Capital Employed for the Quarter Ended 30th June 2026

[Rs. In Lakhs]

		Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
1	1. Segment Revenue				
a	Healthcare	5.93	9.28	9.28	37.08
b	Rent on Leasehold Land	41.33	41.33	41.33	165.31
c	Others	12.59	6.01	12.09	38.27
	Total:	59.85	56.62	62.70	240.66
	Less: Inter Segment Revenue	-	-	-	-
	Net Sales / Income from Operations	59.85	56.62	62.70	240.66
2	Segment Results (Profit / Loss) tax				
a	Healthcare	4.11	6.09	6.18	24.81
b	Rent on Leasehold Land	41.10	41.10	41.10	164.39
c	Others	12.59	6.01	12.09	38.27
	Total:	57.79	53.20	59.37	227.47
	Less:				
	Interest	-	-	-	-
	Other Unallocable Expenditure (Net off)	41.49	45.24	36.24	169.51
	Total Profit before Tax & Exceptional items	**16.30**	**7.96**	**23.13**	**57.96**
3	Capital Employed (Segment Assets - Segment Liabilities)				
a	Healthcare	10.50	69.27	11.89	69.27
b	Leasehold Land	(3.74)	(3.51)	(2.82)	(3.51)
c	Others	810.43	745.73	804.40	745.73
	Total:	817.20	811.48	813.46	811.48

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on 7th August 2026

By order of the Board
Srinivasa Raghavan Mathurakavi Ayyangar
Chairman & Managing Director
DIN: 00090266

Mumbai
07-Aug-26